Inventiva S.A. (IVA) stock
IVANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as IVEVF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 1/30
$3.39+0.17 (+5.28%)
Close on Nov 18, 2026Market cap $655.07MP/E –Yield –
Inventiva r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €87.04M, down 4.2% from the year before. The highest annual figure on record is €110.01M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €87.04M | -4.2% |
| FY2024 | Dec 31, 2024 | €90.88M | -17.4% |
| FY2023 | Dec 31, 2023 | €110.01M | +81.9% |
| FY2022 | Dec 31, 2022 | €60.47M | +24.8% |
| FY2021 | Dec 31, 2021 | €48.45M | +104.3% |
| FY2020 | Dec 31, 2020 | €23.72M | -29.8% |
| FY2019 | Dec 31, 2019 | €33.79M | +6.4% |
| FY2018 | Dec 31, 2018 | €31.76M | – |
See a number that looks wrong?